Wound-care product from Osiris shows positive trial results

Osiris Therapeutics reported that its Grafix wound-care product, which releases stem cells straight to the wound site to allow tissue regeneration, demonstrated effectiveness in treating patients with diabetic foot ulcers in a postmarket study. The study found that complete wound closure was achieved in 62% of patients who were treated with Grafix, compared with 21% of those who received traditional therapy.

View Full Article in:

Reuters · Wall Street Journal (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA